Global Postmenopausal Osteoporosis Drugs Market 2016-2020

Published: May 2016
Pages: 60
SKU: IRTNTR9271

Enjoy complimentary customisation on priority with our Enterprise License!

Get me the latest version!

Outlook of the postmenopausal osteoporosis drugs market

Technavio’s market research analyst predicts the global postmenopausal osteoporosis drugs market to grow steadily at a CAGR of more than 4% over the forecast period. With the expected launch of promising pipeline molecules, the market for postmenopausal osteoporosis has a positive outlook in the coming years. The postmenopausal osteoporosis drugs market is characterized by the presence of promising late-stage molecules that are being developed by the major and upcoming players in this market. Some of the late-stage pipeline molecules that are envisaged to be launched during the forecast period are Tarsa Therapeutics’ TBRIA, romosozumab, Merck’ odanacatib (Phase III), and Radius Health’s abaloparatide (Phase III).

In this industry research report, the analysts have estimated factors such as the emergence of combination therapies to contribute to this market’s growth in the next four years. Anabolic and antiresorptive agents can significantly enhance bone density and strength as a combination therapy than as monotherapy. Clinical trials have been performed evaluating the effect of PTH1-34 or PTH1-84 in combination with antiresorptive drugs, including raloxifene, alendronate, and risedronate. Moreover, it has been observed that combining antiresorptive drugs with PTH or teriparatide has been successful in providing greater bone mineral density. For instance, Pfizer's Duavee is a combination of conjugated estrogens and bazedoxifene used in the treatment of postmenopausal osteoporosis with few side effects.

Segmentation by line of therapy and analysis of the postmenopausal osteoporosis drugs market

First line of therapy
Second line of therapy

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview
Top-vendor offerings

PART 03: Market research methodology

Research methodology
Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Disease overview

Understanding postmenopausal osteoporosis
Epidemiology and demography
Risk factors
Symptoms
Diagnosis
Treatment

PART 06: Key buying criteria

PART 07: Pipeline scenario

TBRIA
Romosozumab (AMG785)
Odanacatib (MK-0822)
Abaloparatide SC/Abaloparatide transdermal patch
PHN-031 (PH3)
NB S101
Teriparatide ZP Patch (ZP-PTH)
Blosozumab (LY2541546)

PART 08: Market landscape

Market overview
Market size and forecast
Five forces analysis

PART 09: Market segmentation by therapeutic class

Antiresorptive medications
Anabolic medications

PART 10: Market segmentation by line of therapy

PART 11: Geographical segmentation

Global postmenopausal osteoporosis drugs market by geographical segmentation 2015-2020
Postmenopausal osteoporosis drugs market in Americas
Postmenopausal osteoporosis drugs market in EMEA
Postmenopausal osteoporosis drugs market in APAC

PART 12: Market drivers